← Leaderboards
Shaoqin - Gong
University Of Wisconsin-Madison
$18,047,338
Attributed
$33,863,274
Total exposure
17
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.9M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,863,274 · 17
By mechanism
R01$10,379,231 · 7
R24$7,812,597 · 1
U19$6,106,772 · 1
UH3$2,404,322 · 1
UG3$2,253,202 · 1
RF1$1,860,250 · 1
Top collaborators
- Lianwang Guo14 shared
- K Craig Kent12 shared
- Christopher A Ahern7 shared
- David M Gamm7 shared
- Bikash Ranjan Pattnaik7 shared
- Marina Emborg5 shared
- Jon E Levine5 shared
- Subhojit Roy5 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Bikash Ranjan Pattnaik$3,466,189
- Christopher A Ahern$11,135,468
- David M Gamm$16,807,477
- Lianwang Guo$8,850,010
- Krishanu Saha$8,638,524
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroPharmaceutical PreparationsCellsMouse ModelEngineeringToxic EffectInnovationNanoparticleFormulationTargeted DeliveryDrug Delivery SystemsNanomedicineProductionGenesBiomaterial CompatibilityDesignTissuesUptakeLigandsSafetyBiodistributionSurfaceFda Approved
Grant awards (46)
Silica Nanocapsule-Mediated Nonviral Delivery of CRISPR Base Editor mRNA and Allele Specific sgRNA for Gene Correction in Leber Congenital Amaurosis$2,189,363
U19 · FY2025 · NS · contact PI
Restoring Vision with High-Fidelity Nonsense Codon Correction$1,684,745
R24 · FY2025 · EY
Epigenetic targeting and nanoplatform-enabled local drug delivery - a two-pronged approach to stenosis prevention after vascular surgery$713,869
R01 · FY2025 · HL
Targeted approach to the mitigation of abdominal aortic aneurysm$709,437
R01 · FY2025 · HL
Mechanistic and Translational Determination of PERK-targeting Strategies for Non-surgical Management of Abdominal Aortic Aneurysm$690,384
R01 · FY2025 · HL
Dual-Stimuli Responsive Antibiotic-Loaded Nanoparticles: A New Strategy to Overcome Antimicrobial Resistance$481,775
R01 · FY2025 · AI · contact PI
A Novel Broad-Spectrum Nanoimmunotherapeutic Approach for Combating Multidrug Resistant Bacteria$392,634
R01 · FY2025 · AI · contact PI
Silica Nanocapsule-Mediated Nonviral Delivery of CRISPR Base Editor mRNA and Allele Specific sgRNA for Gene Correction in Leber Congenital Amaurosis$2,051,273
U19 · FY2024 · NS · contact PI
Restoring Vision with High-Fidelity Nonsense Codon Correction$1,684,745
R24 · FY2024 · EY
Epigenetic targeting and nanoplatform-enabled local drug delivery - a two-pronged approach to stenosis prevention after vascular surgery$729,244
R01 · FY2024 · HL
Targeted approach to the mitigation of abdominal aortic aneurysm$724,978
R01 · FY2024 · HL
Mechanistic and Translational Determination of PERK-targeting Strategies for Non-surgical Management of Abdominal Aortic Aneurysm$678,529
R01 · FY2024 · HL
Dual-Stimuli Responsive Antibiotic-Loaded Nanoparticles: A New Strategy to Overcome Antimicrobial Resistance$486,236
R01 · FY2024 · AI · contact PI
Silica Nanocapsule-Mediated Nonviral Delivery of CRISPR Base Editor mRNA and Allele Specific sgRNA for Gene Correction in Leber Congenital Amaurosis$1,866,136
U19 · FY2023 · NS · contact PI
Brain-Wide Genome Editing Enabled by Intravenously Administered Non-Viral Nanovectors As a Potential Therapy for Alzheimerâs Disease$1,860,250
RF1 · FY2023 · AG · contact PI
Restoring Vision with High-Fidelity Nonsense Codon Correction$1,460,184
R24 · FY2023 · EY
Optimization of CRISPR genome editor and its delivery strategy for C9orf72 frontotemporal dementia$869,959
U01 · FY2023 · NS
Dual-Stimuli Responsive Antibiotic-Loaded Nanoparticles: A New Strategy to Overcome Antimicrobial Resistance$490,606
R01 · FY2023 · AI · contact PI
Development of NAD+ loaded nanoparticles as a safe and efficient strategy to combat sepsis.$229,920
R21 · FY2023 · AI · contact PI
Restoring Vision with High-Fidelity Nonsense Codon Correction$1,443,079
R24 · FY2022 · EY
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$1,212,189
UH3 · FY2022 · NS · contact PI
Stimuli-Responsive Polymer-Drug Conjugates: A New Strategy to Fight Antimicrobial Resistance$229,920
R21 · FY2022 · AI · contact PI
Development of NAD+ loaded nanoparticles as a safe and efficient strategy to combat sepsis.$194,375
R21 · FY2022 · AI · contact PI
Restoring Vision with High-Fidelity Nonsense Codon Correction$42,500
R24 · FY2022 · EY
Restoring Vision with High-Fidelity Nonsense Codon Correction$1,454,844
R24 · FY2021 · EY
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$1,192,133
UH3 · FY2021 · NS · contact PI
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular Surgery$634,517
R01 · FY2021 · HL
Stimuli-Responsive Polymer-Drug Conjugates: A New Strategy to Fight Antimicrobial Resistance$191,661
R21 · FY2021 · AI · contact PI
Restoring Vision with High-Fidelity Nonsense Codon Correction$42,500
R24 · FY2021 · EY
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$750,461
UG3 · FY2020 · NS · contact PI
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular Surgery$595,265
R01 · FY2020 · HL
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$750,461
UG3 · FY2019 · NS · contact PI
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular Surgery$595,265
R01 · FY2019 · HL
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction$313,866
R01 · FY2019 · HL
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$752,280
UG3 · FY2018 · NS · contact PI
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular Surgery$609,265
R01 · FY2018 · HL
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction$483,556
R01 · FY2018 · HL
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction$496,555
R01 · FY2017 · HL
Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling Pathway$198,720
K25 · FY2017 · CA · contact PI
Targeting Triple Negative Breast Cancer Using Nanoparticles Loaded with the Anti-Cancer Drug Aminoflavone$155,321
R21 · FY2017 · CA
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction$553,250
R01 · FY2016 · HL
Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling Pathway$198,720
K25 · FY2016 · CA · contact PI
Targeting Triple Negative Breast Cancer Using Nanoparticles Loaded with the Anti-Cancer Drug Aminoflavone$182,144
R21 · FY2016 · CA
Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling Pathway$198,720
K25 · FY2015 · CA · contact PI
Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling Pathway$198,720
K25 · FY2014 · CA · contact PI
Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling Pathway$198,720
K25 · FY2013 · CA · contact PI